ADMA (ADMA Biologics) Growth Rank: 8 (As of Aug. 01, 2026) — 60% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $8.46
GF Value $18.21
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Growth Rank?

ADMA Biologics ADMA -2.42% 64 Growth Rank is 8 as of Aug. 01, 2026, which is 60% above its 10-year median of 5.00. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.21 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ADMA Biologics has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

ADMA Biologics Growth Rank Related Terms

ADMA vs ZBIO, PGEN, GLUE: Growth Rank Comparison

For the Biotechnology subindustry, ADMA Biologics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADMA Biologics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Growth Rank distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Growth Rank falls into.


ADMA
64GF Score
ADMA Biologics Inc ADMA
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
ADMA Biologics (ADMA) has a Growth Rank of 8 as of Aug. 01, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on ADMA Biologics and its competitors. This is 60% above median its historical median of 5.00. Over the past decade, ADMA Biologics' Growth Rank has ranged from 1.00 to 10.00.
Is ADMA Biologics' Growth Rank too high?
ADMA Biologics' current Growth Rank of 8 is 60% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Growth Rank compare to ZBIO and PGEN?
ADMA Biologics' Growth Rank of 8 can be compared against companies in the Biotechnology industry. Historically, ADMA Biologics' own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Growth Rank is 8, which is 60% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.21, compared to a current price of $8.46 — trading 53.5% below its estimated fair value. The current Growth Rank is 8, which is 60% above median its 10-year median of 5.00. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Growth Rank is 8 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.46 is trading 53.5% below its estimated GF Value™ of $18.21. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Growth Rank: 8 (60% above median its 10-year median of 5.00)
  • GF Value™: $18.21 vs. price of $8.46 (53.5% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.46
Price
$18.21
GF Value